Anti-angiogenic and anti-tumor activities of 2′-hydroxy-4′- methoxychalcone

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 5, 2006, Pages 1028-1031

  Lee, Yeon Sil ^a   Lim, Soon Sung ^a   Shin, Kuk Hyun ^b   Kim, Yeong Shik ^b   Ohuchi, Kazuo ^c   Jung, Sang Hoon ^d  

^a Hallym University   (South Korea)

^b Seoul National University   (South Korea)

^c TOHOKU UNIVERSITY   (Japan)

^d Korea Institute of Science and Technology   (South Korea)

Author keywords

2 hydroxy 4 methoxychalcone; Angiogenesis; Calf pulmonary arterial endothelial cell; Proliferation

Indexed keywords

2' HYDROXY 4' METHOXYCHALCONE; BASIC FIBROBLAST GROWTH FACTOR; CHALCONE DERIVATIVE; COLLAGENASE; CYCLOOXYGENASE 2; GELATINASE; MATRIGEL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INDUCTION; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MOUSE; NONHUMAN; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CATTLE; CELL LINE; CELL PROLIFERATION; CHALCONE; CHALCONES; CHICK EMBRYO; COLLAGENASES; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTORS; GELATINASES; HEPARIN; LLC-PK1 CELLS; MICE; MICE, INBRED C57BL; SARCOMA 180; SWINE;

EID: 33646440301     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.1028     Document Type: Article

References (20)

1. Hyder S. M., Stancel G. M., Mol. Endocrinol., 13, 806-811 (1999).
2. Folkman J., Nat. Med., 1, 27-31 (1995).
3. Koch A. E., Arthritis Rheum., 41, 951-962 (1998).
4. Ferrara N., Alitalo K., Nat. Med., 5, 1359-1364 (1999).
5. Powell J., Curr. Opin. Pediatr., 11, 457-463 (1999).
6. Hanahan D., Nat. Med., 4, 13-14 (1998).
7. Go M. L., Wu X., Liu X. L., Curr. Med. Chem., 12, 2915-2921 (2005).
8. Williams C. S., Smalley W., DuBois R. N., J. Clin. Invest., 100, 1325-1329 (1997).
9. Kim Y. P., Ban H. S., Lim S. S., Kimura N., Jung S. H., Ji J., Lee S., Ryu N., Keum S. R., Shin K. H., Ohuchi K., J. Pharm. Pharmacol., 53, 1295-1302 (2001).
10. Lim S. S., Jung S. H., Ji J., Shin K. H., Keum S. R., Chem. Pharm. Bull., 48, 1786-1789 (2000).
11. Oikawa T., Hirotani K., Ogasawara H., Katayama T., Nakamura O., Iwaguchi T., Hiragun A., Eur. J. Pharmacol., 178, 247-250 (1990).
12. Tanaka N. G., Sakamoto N., Tohgo A., Nishiyama Y., Ogawa H., Exp. Pathol., 30, 143-150 (1986).
13. Suh H., Jung E. J., Kim T. H., Lee H. Y., Park Y. H., Kim K. W., Cancer Lett., 113, 117-122 (1997).
14. Denholm E. M., Lin Y. Q., Silver P. J., Eur. J. Pharmacol., 416, 213-221 (2001).
15. Passaniti A., Taylor R. M., Pili R., Guo Y., Long P. V., Haney J. A., Pauly R. R., Grant D. S., Martin G. R., Lab. Invest., 67, 519-528 (1992).
16. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J., Cell, 79, 315-328 (1994).
17. Hernandez G. L., Volpert O. V., Iniguez M. A., Lorenzo E., Martinez-Martinez S., Grau R., Fresno M., Redondo J. M., J. Exp. Med., 193, 607-620 (2001).
18. Tsuji S., Tsujii M., Kawano S., Hori M., J. Exp. Clin. Cancer Res., 20, 117-129 (2001).
19. Masferrer J. L., Leahy K. M., Koki A. T., Zweifel B. S., Settle S. L., Woerner B. M., Edwards D. A., Flickinger A. G., Moore R. J., Seibert K., Cancer Res., 60, 1306-1311 (2000).
20. Lee K. T., Sohn I. C., Kim Y. K., Choi J. H., Choi J. W., Park H. J., Itoh Y., Miyamoto K., Biol. Pharm. Bull., 24, 1117-1121 (2001).